drugset / Trial / NCT00909857

Effect on Primary Dysmenorrhea

NCT00909857

Phase 3 Completed 507 enrolled Bayer
RandomizedParallel-groupTriple-blindTreatment

Summary

To investigate the potential benefits of a new oral contraceptive (SH T00658ID) on alleviating complaints of dysmenorrhea associated with oral contraceptive use.

Timeline

Start
2009-04
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Dienogest Small molecule Oral
Comparator Levonorgestrel Small molecule Oral
Subject estradiol valerate Unknown Oral
Comparator ethinyl estradiol Small molecule Oral

Indications